Continuation of Proton Pump Inhibitors from Hospital to Community
- 170 Downloads
To evaluate the appropriateness of initiation of proton pump inhibitor (PPI) treatment in hospital, the quality of discharge information, and any association with continued treatment in the community.
Survey of all inpatients newly initiated on a PPI in June–August 2003. Assessment of appropriateness of therapy and completeness of discharge information; assessment of continuation of PPI therapy in the community after 6 months.
Thirty-five of 58 patients (60%) were considered appropriately commenced on PPI treatment. Less than 25% of patients discharged on a PPI had discharge information recommending duration of treatment or review. In the “appropriate” group 30 patients (86%) were discharged on omeprazole, and 13/21 (62%) evaluable patients remained on this at 6 months. In the “inappropriate” group 15 (65%) were discharged on omeprazole, and 10/14 (71%) evaluable patients remained on this at 6 months. Older patients remained on omeprazole for a longer duration but appropriateness of commencement did not influence the duration of treatment. Dose titration was attempted for 10 (29%) patients including three from the “inappropriate” group.
Care should be taken to commence PPIs only when clinically indicated. Discharge information to GPs, especially recommendations for duration of treatment and/or dose titration, requires improvement.
KeywordsDrug use study Hospital discharge Hospital prescribing New Zealand Proton pump inhibitors
Unable to display preview. Download preview PDF.
The authors would like to thank the hospital pharmacists who assisted with this project and The New Zealand Pharmacy Education and Research Foundation who supported the project by providing a summer studentship grant.
- 2.Church N, Palmer K. Acute non-variceal gastrointestinal haemorrhage treatment. In: Mc Donald J, Burroughs A, Feagan B, editors, Evidence based gastroenterology and hepatology. BMJ Books: London, 2002. p. 118–39. ISBN 072791751X.Google Scholar
- 4.Pharmaceutical Management Agency, Annual Review 2004, Wellington, New Zealand: Pharmaceutical Management Agency, 2004.Google Scholar
- 5.Australian Department of Health and Aging, Expenditure and prescriptions twelve months to 31 March 2004. In: Pharmaceutical benefits scheme. 2 September 2004. http://www.health.gov.au/pbs/general/pubs/pbbexp/pbmar04/index. htm (3 Aug 2005).
- 6.Department of Health, Prescription Cost Analysis: England 2004. London: Department of Health, 2005.Google Scholar
- 7.Stowasser DA, McGuire TM, Petrie GM, et al. Information quality: a major consideration in the development of medication liaison services. Aust J Hosp Pharm 1997;27:362–6.Google Scholar
- 10.New Zealand Guidelines Group, Management of dyspepsia and heartburn, Wellington, New Zealand: New Zealand Guidelines Group, 2004. p. 1–118.Google Scholar